ClinicalTrials.gg
TerminatedNCT05086744Updated Oct 16, 2025Results posted

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

A Phase 2 interventional study of Iptacopan in Immune Thrombocytopenia (ITP) and Cold Agglutinin Disease (CAD), sponsored by Novartis Pharmaceuticals. Terminated at 8 sites in 6 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Enrollment
10th of 12
19 · median 39
Started
2021
the only one that year
Phase 2
7 of 17
2 open now
Registered
7th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 7th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

The main purpose of this study was to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

Read the detailed description

This was an open-label, single-arm (within each cohort), multi-center, non-confirmatory basket study to assess the efficacy, safety and pharmacokinetics of iptacopan in participants with autoimmune benign hematological disorders. The study was set up as a basket study to allow inclusion of new cohorts (indications). The study included 2 cohorts: primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). Participants in Cohort 1 (ITP) were stratified in two groups according to high/low complement activation (i.e., based on sC5b-9 level at screening). No additional cohorts were added during the study.

The study consisted of a screening period, a 12-week treatment period (Part A), a washout (for responders)/follow-up (for non-responders) period after Part A, and, for responders only, an additional treatment extension period for up to 24 months (Part B). Non-responders who had signs of clinical benefit according to the Investigator's assessment could also continue treatment with iptacopan in Part B. The washout period prior to the start of part B lasted up to 4 weeks.

03

Conditions studied

  • Immune Thrombocytopenia (ITP)
  • Cold Agglutinin Disease (CAD)

Keywords

  • LNP023
  • Iptacopan
  • Immune thrombocytopenia
  • Cold agglutinin disease
  • Autoimmune benign hematological disorders
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Cohorts:

  • Written
  • Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections was required and vaccination against Haemophilus influenzae infection is recommended prior to the start of treatment.
  • Weight of at least 35 kg

Cohort 1 specific inclusion criteria:

  • Participants with a diagnosis of persistent or chronic primary ITP
  • Participants must have received at least 1 unique prior therapy administered with the intention to treat ITP
  • Sustained thrombocytopenia

Cohort 2 specific inclusion criteria:

  • Participants with a diagnosis of primary CAD
  • Participants must have received at least 1 unique prior therapy administered with the intention to treat CAD
  • Laboratory evidence of ongoing hemolysis
  • Sustained anemia

Exclusion criteria

Exclusion Criteria:

All cohorts:

  • Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
  • Past or concomitant use of medications prohibited by the protocol
  • Known or suspected hereditary or acquired complement deficiency
  • History of primary or secondary immunodeficiency, including a positive test result
  • Chronic infection with or C virus
  • History of recurrent invasive infections caused by encapsulated organisms, including Neisseria meningitidis, Streptococcus pneumoniae, or Haemophilus influenzae
  • Presence or suspicion of any active infection within 14 days prior to first study drug administration.
  • Any medical condition deemed likely to interfere with the participant's participation in the study
  • Any malignant disease diagnosed within the past 5 years, with the exception of localized non-melanoma skin cancer, in situ cervical cancer, or, for CAD, a low-grade lymphoproliferative disorder.
  • History of bone marrow/hematopoietic stem cell or solid organ transplantation.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during dosing of investigational drug and for 1 week after last iptacopan dose
  • Active severe bleeding or history of intracranial hemorrhage.
  • Liver disease, or liver injury as indicated by abnormal liver function tests.
  • Severe concurrent comorbidities of unstable medical conditions.

Cohort 1 specific exclusion criteria:

  • Secondary ITP, as may arise in the setting of certain disorders, immunodeficiency syndromes, infections, , and drug treatments
  • No ITP-directed background therapy permitted, with the exception of either a thrombopoietin receptor agonist or low-dose , as long as stable dosage for at least 4 weeks prior to first iptacopan dose
  • Abnormal coagulation screening labs

Cohort 2 specific exclusion criteria:

  • Secondary cold agglutinin syndrome, as may arise in the setting of certain infections, autoimmune disorders, and malignancies (with the exception of a low-grade lymphoproliferative disorder)
  • No CAD-directed background therapy permitted
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Iptacopan 200 mg BID

    Iptacopan 200 mg twice daily (BID) in participants with primary ITP and primary CAD

    Drug: Iptacopan

Interventions

  • Iptacopan 200 mg BID given orally (capsule)

    Also known as: Investigational new drug, company code: LNP023

06

What researchers measure

Primary outcomes

  1. Cohort 1 (ITP): Number of Participants With a Clinically Meaningful Response

    A study participant with ITP was considered a responder if all the below criteria were met: 1. Platelet count of ≥50 k/μL sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat ITP 3. Lack of treatment discontinuation

    Time frame: Up to 12 weeks (Part A)

  2. Cohort 2 (CAD): Number of Participants With a Clinically Meaningful Response

    A study participant with CAD was considered a responder if all the below criteria were met: 1. Hemoglobin level increase of ≥1.5 g/dL above baseline sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat CAD 3. Lack of treatment discontinuation

    Time frame: Baseline, up to 12 weeks (Part A)

Secondary outcomes

  1. Cohort 1 (ITP): Time to First Platelet Count ≥50 k/μL

    The first time that a participant had a platelet count ≥50 k/μL after first dose of study treatment. Time to the first response was assessed for responders only.

    Time frame: Up to 12 weeks (Part A)

  2. Cohort 2 (CAD): Time to First Hemoglobin Level ≥1.5 g/dL Above Baseline

    The first time that a participant had a hemoglobin level ≥1.5 g/dL above baseline after first dose of study treatment. Time to the first response was assessed for responders only.

    Time frame: Baseline, up to 12 weeks (Part A)

  3. Cohort 1 (ITP): Duration of Time During Which Platelet Count Remains ≥50 k/μL Without the Use of Rescue Therapy

    The duration of response corresponds to the duration of time during which a participant's platelet count remains ≥50 k/μL without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.

    Time frame: Up to 12 weeks (Part A)

  4. Cohort 2 (CAD): Duration of Time During Which Hemoglobin Level Remains ≥1.5 g/dL Above Baseline Without the Use of Rescue Therapy

    The duration of response corresponds to the duration of time during which a participant's hemoglobin level remained ≥1.5 g/dL above baseline without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.

    Time frame: Baseline, up to 12 weeks (Part A)

  5. Cohort 1 (ITP): Magnitude of Platelet Count Increase From Baseline

    The magnitude of increase in platelet count compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: absolute platelet counts increase \<50, ≥50 and \<100, ≥100 and \<150, and ≥150 k/uL. This endpoint is only applicable to participants without rescue therapy in the treatment period.

    Time frame: Baseline, up to 12 weeks (Part A)

  6. Cohort 2 (CAD): Magnitude of Hemoglobin Increase From Baseline

    The magnitude of increase in hemoglobin level compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: Hb increase from baseline by \<1, ≥1 and \<1.5, ≥1.5 and \<2, and ≥2 g/dL. This endpoint is only applicable to participants without rescue therapy in the treatment period.

    Time frame: Baseline, up to 12 weeks (Part A)

  7. Cohort 1 (ITP): Need for Rescue Therapy During Part A

    Rescue therapy was defined as any therapy with ITP indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For ITP, rescue therapy generally consisted of corticosteroids, intravenous immunoglobulins or anti-Rho(D) immunoglobulin and may had been indicated in case of worsening thrombocytopenia and/or signs or symptoms of bleeding.

    Time frame: Up to 12 weeks (Part A)

  8. Cohort 2 (CAD): Need for Rescue Therapy During Part A

    Rescue therapy was defined as any therapy with CAD indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For CAD, rescue therapy generally consisted of plasmapheresis, intravenous immunoglobulins (IVIG) and/or red blood cell transfusions and may had been indicated in case of worsening anemia and/or critical hemolysis.

    Time frame: Up to 12 weeks (Part A)

  9. Cohort 2 (CAD): Change From Baseline in Lactate Dehydrogenase (LDH)

    LDH was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

    Time frame: Baseline, up to 12 weeks (Part A)

  10. Cohort 2 (CAD): Change From Baseline in Total Bilirubin

    Total bilirubin was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

    Time frame: Baseline, up to 12 weeks (Part A)

  11. Cohort 2 (CAD): Change From Baseline in Reticulocyte Count

    Reticulocyte count was measured in blood samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

    Time frame: Baseline, up to 12 weeks (Part A)

  12. Cohort 2 (CAD): Change From Baseline in Haptoglobin

    Haptoglobin was measured in serum or plasma samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

    Time frame: Baseline, up to 12 weeks (Part A)

  13. Cohort 1 and 2: Number of Participants With AEs and SAEs During the On-treatment Period in Part A and B

    Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of study drug up to 7 days after the last administration of study drug.

    Time frame: From first dose of study treatment to 7 days after last dose, up to approximately 43 weeks (Cohort 1) and 103 weeks (Cohort 2)

  14. Cohort 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Iptacopan

    Pharmacokinetic (PK) parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

    Time frame: Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A

  15. Cohort 1 and 2: Time to Maximum Observed Plasma Concentration (Tmax) of Iptacopan

    PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.

    Time frame: Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A

  16. Cohort 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Iptacopan

    PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for area under the curve (AUC) calculation.

    Time frame: Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A

  17. Cohort 1 and 2: Trough Plasma Concentration (Ctrough) of Iptacopan

    Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.

    Time frame: Pre-dose on Day 15, 29 and 57 of Part A

07

Results

Posted Mar 19, 2025

Participant flow

Participants took part in 8 investigative sites in 6 countries.

Part A
Participant flow — Part A
MilestoneCohort 1 (ITP)Cohort 2 (CAD)
Started910
Pd analysis set810
Itp - sc5b-9 low50
Itp - sc5b-9 high40
Completed49
Not completed51
Withdrew: Adverse event01
Withdrew: Lack of efficacy30
Withdrew: Protocol deviation10
Withdrew: Subject decision10
Part B
Participant flow — Part B
MilestoneCohort 1 (ITP)Cohort 2 (CAD)
Started18
Itp - sc5b-9 high10
Itp - sc5b-9 low00
Completed00
Not completed18
Withdrew: Adverse event01
Withdrew: Lack of efficacy01
Withdrew: Study terminated by sponsor16

Outcome measures

PrimaryCohort 1 (ITP): Number of Participants With a Clinically Meaningful Response

A study participant with ITP was considered a responder if all the below criteria were met: 1. Platelet count of ≥50 k/μL sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat ITP 3. Lack of treatment discontinuation

Time frame:
Up to 12 weeks (Part A)
Reported as:
Count of participants · Participants
Cohort 1 (ITP): Number of Participants With a Clinically Meaningful Response
ParticipantsCohort 1 (ITP) - sC5b-9 HighCohort 1 (ITP) - sC5b-9 LowCohort 1 (ITP)
Cohort 1 (ITP): Number of Participants With a Clinically Meaningful Response000
PrimaryCohort 2 (CAD): Number of Participants With a Clinically Meaningful Response

A study participant with CAD was considered a responder if all the below criteria were met: 1. Hemoglobin level increase of ≥1.5 g/dL above baseline sustained for at least 2 consecutive weeks during the main, 12-week treatment part 2. Absence of rescue therapy or prohibited medications to treat CAD 3. Lack of treatment discontinuation

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Count of participants · Participants
Cohort 2 (CAD): Number of Participants With a Clinically Meaningful Response
ParticipantsCohort 2 (CAD)
Cohort 2 (CAD): Number of Participants With a Clinically Meaningful Response5
SecondaryCohort 1 (ITP): Time to First Platelet Count ≥50 k/μL

The first time that a participant had a platelet count ≥50 k/μL after first dose of study treatment. Time to the first response was assessed for responders only.

Time frame:
Up to 12 weeks (Part A)

No measurements were reported for this outcome.

SecondaryCohort 2 (CAD): Time to First Hemoglobin Level ≥1.5 g/dL Above Baseline

The first time that a participant had a hemoglobin level ≥1.5 g/dL above baseline after first dose of study treatment. Time to the first response was assessed for responders only.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Median · days
Cohort 2 (CAD): Time to First Hemoglobin Level ≥1.5 g/dL Above Baseline
daysCohort 2 (CAD)
Cohort 2 (CAD): Time to First Hemoglobin Level ≥1.5 g/dL Above Baseline29.0 (23 to 63)
SecondaryCohort 1 (ITP): Duration of Time During Which Platelet Count Remains ≥50 k/μL Without the Use of Rescue Therapy

The duration of response corresponds to the duration of time during which a participant's platelet count remains ≥50 k/μL without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.

Time frame:
Up to 12 weeks (Part A)

No measurements were reported for this outcome.

SecondaryCohort 2 (CAD): Duration of Time During Which Hemoglobin Level Remains ≥1.5 g/dL Above Baseline Without the Use of Rescue Therapy

The duration of response corresponds to the duration of time during which a participant's hemoglobin level remained ≥1.5 g/dL above baseline without the use of rescue therapy. The duration of response was considered as cumulative if there were non-continuous periods of response. Duration of response was analyzed for responders only.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Median · days
Cohort 2 (CAD): Duration of Time During Which Hemoglobin Level Remains ≥1.5 g/dL Above Baseline Without the Use of Rescue Therapy
daysCohort 2 (CAD)
Cohort 2 (CAD): Duration of Time During Which Hemoglobin Level Remains ≥1.5 g/dL Above Baseline Without the Use of Rescue Therapy56.0 (28 to 63)
SecondaryCohort 1 (ITP): Magnitude of Platelet Count Increase From Baseline

The magnitude of increase in platelet count compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: absolute platelet counts increase \<50, ≥50 and \<100, ≥100 and \<150, and ≥150 k/uL. This endpoint is only applicable to participants without rescue therapy in the treatment period.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Count of participants · Participants
Cohort 1 (ITP): Magnitude of Platelet Count Increase From Baseline
ParticipantsCohort 1 (ITP) - sC5b-9 HighCohort 1 (ITP) - sC5b-9 LowCohort 1 (ITP)
Absolute platelet counts increase <50 k/uL123
Absolute platelet counts increase >=50 k/uL and <100 k/uL000
Absolute platelet counts increase >=100 k/uL and <150 k/uL000
Absolute platelet counts increase >=150 k/uL000
SecondaryCohort 2 (CAD): Magnitude of Hemoglobin Increase From Baseline

The magnitude of increase in hemoglobin level compared to baseline was derived for each participant at each visit and time point. Best response across all visits is presented (highest value). The following categories were used: Hb increase from baseline by \<1, ≥1 and \<1.5, ≥1.5 and \<2, and ≥2 g/dL. This endpoint is only applicable to participants without rescue therapy in the treatment period.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Count of participants · Participants
Cohort 2 (CAD): Magnitude of Hemoglobin Increase From Baseline
ParticipantsCohort 2 (CAD)
Hb increase by <1.0 g/dL2
Hb increase by >=1.0 g/dL and <1.5 g/dL1
Hb increase by =>1.5 g/dL and <2 g/dL2
Hb increase by =>2 g/dL4
SecondaryCohort 1 (ITP): Need for Rescue Therapy During Part A

Rescue therapy was defined as any therapy with ITP indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For ITP, rescue therapy generally consisted of corticosteroids, intravenous immunoglobulins or anti-Rho(D) immunoglobulin and may had been indicated in case of worsening thrombocytopenia and/or signs or symptoms of bleeding.

Time frame:
Up to 12 weeks (Part A)
Reported as:
Count of participants · Participants
Cohort 1 (ITP): Need for Rescue Therapy During Part A
ParticipantsCohort 1 (ITP) - sC5b-9 HighCohort 1 (ITP) - sC5b-9 LowCohort 1 (ITP)
No123
Yes235
SecondaryCohort 2 (CAD): Need for Rescue Therapy During Part A

Rescue therapy was defined as any therapy with CAD indication that started on or after Day 1. Rescue therapy, if indicated, could be initiated at the Investigator's discretion. From Day 1 onwards, if rescue therapy was needed before response criteria were met, the participant was treated as a non-responder. Conversely, use of rescue therapy after the primary endpoint was met, would not impact the response status with respect to that endpoint. For CAD, rescue therapy generally consisted of plasmapheresis, intravenous immunoglobulins (IVIG) and/or red blood cell transfusions and may had been indicated in case of worsening anemia and/or critical hemolysis.

Time frame:
Up to 12 weeks (Part A)
Reported as:
Count of participants · Participants
Cohort 2 (CAD): Need for Rescue Therapy During Part A
ParticipantsCohort 2 (CAD)
No9
Yes1
SecondaryCohort 2 (CAD): Change From Baseline in Lactate Dehydrogenase (LDH)

LDH was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Mean · Units/liter (U/L)
Cohort 2 (CAD): Change From Baseline in Lactate Dehydrogenase (LDH)
Units/liter (U/L)Cohort 2 (CAD)
Cohort 2 (CAD): Change From Baseline in Lactate Dehydrogenase (LDH)-277.83 ± 88.966
SecondaryCohort 2 (CAD): Change From Baseline in Total Bilirubin

Total bilirubin was measured in serum samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Mean · micromole/liter (μmol/L)
Cohort 2 (CAD): Change From Baseline in Total Bilirubin
micromole/liter (μmol/L)Cohort 2 (CAD)
Cohort 2 (CAD): Change From Baseline in Total Bilirubin-15.63 ± 12.979
SecondaryCohort 2 (CAD): Change From Baseline in Reticulocyte Count

Reticulocyte count was measured in blood samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Mean · reticulocytes * 10^9/liter
Cohort 2 (CAD): Change From Baseline in Reticulocyte Count
reticulocytes * 10^9/literCohort 2 (CAD)
Cohort 2 (CAD): Change From Baseline in Reticulocyte Count-37.45 ± 17.205
SecondaryCohort 2 (CAD): Change From Baseline in Haptoglobin

Haptoglobin was measured in serum or plasma samples to assess the effect of treatment with iptacopan on relevant disease biomarkers.

Time frame:
Baseline, up to 12 weeks (Part A)
Reported as:
Mean · gram/liter (g/L)
Cohort 2 (CAD): Change From Baseline in Haptoglobin
gram/liter (g/L)Cohort 2 (CAD)
Cohort 2 (CAD): Change From Baseline in Haptoglobin0.12 ± 0.236
SecondaryCohort 1 and 2: Number of Participants With AEs and SAEs During the On-treatment Period in Part A and B

Number of participants with AEs (any adverse events regardless of seriousness) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For CTCAE v5.0, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of study drug up to 7 days after the last administration of study drug.

Time frame:
From first dose of study treatment to 7 days after last dose, up to approximately 43 weeks (Cohort 1) and 103 weeks (Cohort 2)
Reported as:
Count of participants · Participants
Cohort 1 and 2: Number of Participants With AEs and SAEs During the On-treatment Period in Part A and B
ParticipantsCohort 1 (ITP)Cohort 2 (CAD)
AEs79
Treatment-related AEs23
Severe AEs10
Treatment-related severe AEs10
SAEs01
Treatment-related SAEs00
Fatal SAEs00
Treatment-related fatal SAEs00
SecondaryCohort 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Iptacopan

Pharmacokinetic (PK) parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed concentration following a dose.

Time frame:
Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A
Reported as:
Mean · ng/mL
Cohort 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Iptacopan
ng/mLCohort 1 (ITP)Cohort 2 (CAD)
Day 153190.0 ± 465.004800.0 ± 838.00
Day 572940.0 ± 1020.004420.0 ± 1300.00
SecondaryCohort 1 and 2: Time to Maximum Observed Plasma Concentration (Tmax) of Iptacopan

PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) observed concentration following a dose. Actual sampling times were considered for the calculation of PK parameters.

Time frame:
Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A
Reported as:
Median · hours
Cohort 1 and 2: Time to Maximum Observed Plasma Concentration (Tmax) of Iptacopan
hoursCohort 1 (ITP)Cohort 2 (CAD)
Day 152 (0.75 to 5.15)1 (1 to 2)
Day 572 (2 to 2)1.97 (1 to 2)
SecondaryCohort 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Iptacopan

PK parameters were calculated based on iptacopan plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for area under the curve (AUC) calculation.

Time frame:
Pre-dose, 0.5, 2, 4 and 6 hours after iptacopan administration on Day 15 and Day 57 of Part A
Reported as:
Mean · hr*ng/mL
Cohort 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Iptacopan
hr*ng/mLCohort 1 (ITP)Cohort 2 (CAD)
Day 1524200.0 ± 6110.0031100.0 ± 5830.00
Day 5721300.0 ± 5280.0028200.0 ± 6880.00
SecondaryCohort 1 and 2: Trough Plasma Concentration (Ctrough) of Iptacopan

Ctrough is defined as the concentration reached immediately before the next dose is administered. All drug concentrations below the lower limit of quantification were treated as zero for the calculation of PK parameters.

Time frame:
Pre-dose on Day 15, 29 and 57 of Part A
Reported as:
Mean · ng/mL
Cohort 1 and 2: Trough Plasma Concentration (Ctrough) of Iptacopan
ng/mLCohort 1 (ITP)Cohort 2 (CAD)
Day 151670.0 ± 1320.001980.0 ± 1720.00
Day 291670.0 ± 927.001330.0 ± 337.00
Day 571680.0 ± 758.001410.0 ± 320.00

Adverse events

Collected over From first dose of study treatment to 30 days after last dose, up to approximately 46 weeks (Cohort 1) and 106 weeks (Cohort 2). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (ITP)0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Cohort 2 (CAD)0/10 (0%)1/10 (10%)9/10 (90%)
All Patients0/19 (0%)2/19 (10.5%)16/19 (84.2%)
Most frequent serious events
Most frequent serious events
EventCohort 1 (ITP)Cohort 2 (CAD)All Patients
Haemorrhage intracranialNervous system disorders1/90/101/19
HeadacheNervous system disorders1/90/101/19
Blood creatinine increasedInvestigations0/91/101/19
Acute kidney injuryRenal and urinary disorders0/91/101/19
Most frequent other events
Showing 10 of 54
Most frequent other events
EventCohort 1 (ITP)Cohort 2 (CAD)All Patients
PetechiaeSkin and subcutaneous tissue disorders3/90/103/19
AstheniaGeneral disorders0/93/103/19
HeadacheNervous system disorders2/93/105/19
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/90/102/19
ConstipationGastrointestinal disorders0/92/102/19
NauseaGastrointestinal disorders1/92/103/19
PyrexiaGeneral disorders0/92/102/19
NasopharyngitisInfections and infestations0/92/102/19
Respiratory tract infectionInfections and infestations0/92/102/19
Back painMusculoskeletal and connective tissue disorders0/92/102/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1 (ITP)Cohort 2 (CAD)Total
Mean44.2 ± 20.7766.7 ± 10.0156.1 ± 19.36
Age, Customized
Age, Customized(Participants)Cohort 1 (ITP)Cohort 2 (CAD)Total
18 - <65 years7512
65 - <85 years257
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (ITP)Cohort 2 (CAD)Total
Female51015
Male404
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (ITP)Cohort 2 (CAD)Total
Asian303
White61016
Platelets
Platelets(platelets*10^9/liter)Cohort 1 (ITP)Cohort 2 (CAD)Total
Mean14.6 ± 10.53—14.6 ± 10.53
Hemoglobin
Hemoglobin(gram/liter)Cohort 1 (ITP)Cohort 2 (CAD)Total
Mean—86.7 ± 9.0686.7 ± 9.06
08

Study locations

8 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    Barcelona, Catalonia 08035, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Murcia, 30008, Spain
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
09

References and documents

Publications

  • Roth A, Barcellini W, Ademokun C, Jang J, Lozano ML, Ferreiras DV, Pascual-Izquierdo C, Chitnis S, Matviykiv S, Vitaliti A, Chen C, Katsanou V, Chawla R, Al-Samkari H. Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial. Am J Hematol. 2026 Feb;101(2):242-254. doi: 10.1002/ajh.70147. Epub 2025 Dec 9. PubMed 41366634 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient level data and supporting clinical documents from applicable studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Sep 2023, 20 months.

Results were first posted in Mar 2025, 1 year 5 months after primary completion. A results delay was requested in Jun 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 21, 2021
StartActual
Dec 21, 2021
Primary completionActual
Sep 20, 2023
CompletionActual
May 17, 2024
Results delay requested
Jun 3, 2024
Results first posted
Mar 19, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05086744
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Dec 21, 2021
Primary completion
Sep 20, 2023
Completion
May 17, 2024
Results posted
Mar 19, 2025
Last update
Oct 16, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iptacopan

Start the discussion